93923-57-0 Usage
Derivative of benzoic acid
2-(4-amino-3-nitrobenzoyl)benzoic acid is derived from benzoic acid, which is a simple carboxylic acid.
Yellow crystalline solid
The physical appearance of the compound, which is a yellow-colored crystalline solid.
Industrial applications
The compound has various uses in industries, such as the manufacture of pharmaceuticals and dyes.
Intermediate in synthesis of pharmaceuticals
It serves as an intermediate compound in the production of other pharmaceuticals, aiding in their chemical synthesis.
Precursor in production of dyes
The compound is used as a starting material in the creation of various dyes.
Amino group presence
The chemical structure of the compound contains an amino group (-NH2), which allows for further chemical reactions and modifications.
Nitro group presence
The presence of a nitro group (-NO2) in the structure makes it a versatile building block for the synthesis of a wide range of organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 93923-57-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,9,2 and 3 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 93923-57:
(7*9)+(6*3)+(5*9)+(4*2)+(3*3)+(2*5)+(1*7)=160
160 % 10 = 0
So 93923-57-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H10N2O5/c15-11-6-5-8(7-12(11)16(20)21)13(17)9-3-1-2-4-10(9)14(18)19/h1-7H,15H2,(H,18,19)
93923-57-0Relevant articles and documents
ANTI-CANCER COMPOUNDS
-
Paragraph 0202, (2016/12/12)
This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
RAF MODULATORS AND METHODS OF USE
-
Page/Page column 65-68; 83-84, (2010/02/14)
The present invention relates to compounds of the Formula I, wherein G, A, X1, X2, X3, Z, E, Y, and X are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.
